Craig Hallum Issues Positive Forecast for Xeris Biopharma (NASDAQ:XERS) Stock Price

Xeris Biopharma (NASDAQ:XERS) had its target price lifted by Craig Hallum from $5.00 to $6.50 in a research note published on Friday morning,Benzinga reports. Craig Hallum currently has a buy rating on the stock.

Other equities analysts have also issued research reports about the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $6.00 target price (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday. Finally, Piper Sandler reiterated a “neutral” rating and issued a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a research note on Friday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $5.90.

Xeris Biopharma Trading Up 2.7 %

Shares of NASDAQ:XERS opened at $4.24 on Friday. The stock has a market capitalization of $632.10 million, a PE ratio of -9.42 and a beta of 2.32. Xeris Biopharma has a 1 year low of $1.69 and a 1 year high of $4.50. The firm has a fifty day moving average price of $3.57 and a 200 day moving average price of $3.26.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. NewEdge Advisors LLC acquired a new stake in Xeris Biopharma during the 4th quarter worth $34,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Xeris Biopharma in the third quarter worth about $35,000. R Squared Ltd acquired a new stake in shares of Xeris Biopharma during the fourth quarter worth about $42,000. Quantbot Technologies LP bought a new position in shares of Xeris Biopharma during the 3rd quarter valued at about $44,000. Finally, Cibc World Markets Corp acquired a new position in shares of Xeris Biopharma in the 4th quarter valued at approximately $44,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.